



December 27, 2021

Name of Company: Meiji Holdings Co., Ltd.

Name of Representative: Kazuo Kawamura, CEO, President and Representative Director

Code Number: 2269, 1st Section, Tokyo Stock Exchange

(Amendment in disclosure matters) Notice regarding Company Split (Absorption-Type Company Split) and Transfer of Agricultural Chemicals Manufacturing and Sales Business (Change of Second-Generation Subsidiary)

Meiji Holdings Co., Ltd. (hereinafter referred to as the "Company") announced on September 10, 2021 that (i) Meiji Seika Pharma Co., Ltd. (hereinafter referred to as "MSP"), the Company's consolidated subsidiary, shall have a newly established, wholly owned subsidiary of it named MMAG Co., Ltd. (hereinafter referred to as "NewCo") succeed the Agricultural Chemicals Manufacturing and Sales Business (the assets include all shares of Meiji Agro Chemical Co., Ltd. and Meiji Pharma Korea Co., Ltd. which are wholly owned subsidiaries of MSP) through an absorption-type company split, thereafter, (ii) MSP shall transfer all shares of NewCo to Mitsui Chemicals Agro, Inc. which is wholly owned subsidiaries of Mitsui Chemicals, Inc. (hereinafter referred to as "Mitsui Chemicals Agro"). However, the Company hereby announces that MSP has determined in its board of directors today, with the consent of Mitsui Chemicals Agro, Inc. to amend transfer price (hereinafter referred to as the "Amendment") stated in the announcement of "3. Outline of the Share Transfer (3) Number of Shares Transferred and Status of Shares Held Before and After the Transfer Second-Generation Subsidiary (NewCo)" within the announcement that was made in "Notice regarding Company Split (Absorption-Type Company Split) and Transfer of Agricultural Chemicals Manufacturing and Sales Business (Change of Second-Generation Subsidiary)".

1. Overview of the Amendment

(Before the amendment)

(3) Transfer Price	JPY 46,700 million (approximation)
--------------------	------------------------------------

(After the amendment)

(3) Transfer Price	JPY 42,200 million (approximation)
--------------------	------------------------------------

2. Reason of the Amendment

The transfer price has been amended based on good faith negotiations with the counterparty due to some changes in the prospects assumed when the original transfer price was determined.

3. Future Prospects

Since the impact of this amendment on the consolidated operations of the Company is minor, there is no revision to the consolidated earnings forecast for the fiscal year ending March 31, 2022.

#####